Patents by Inventor Moya Caffrey

Moya Caffrey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adamantane derivatives
    Publication number: 20090176853
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: December 4, 2008
    Publication date: July 9, 2009
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Chemical Compounds
    Publication number: 20090118513
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 7, 2009
    Applicant: AstraZeneca AB
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Chemical compounds
    Patent number: 7495013
    Abstract: The present invention relates to compounds of formula (I): The variables recited in formula (I) are defined in the specification. The present invention also relates to processes of preparing compounds of formula (I) and uses of such compounds for treating a chemokine (e.g., CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: February 24, 2009
    Assignee: AstraZeneca AB
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Adamantane derivatives
    Publication number: 20080139636
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: June 20, 2007
    Publication date: June 12, 2008
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
    Patent number: 7227038
    Abstract: The invention provides compounds of formula in which m, n, R1, R2, R3, R4, and R5, have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Grant
    Filed: February 19, 2004
    Date of Patent: June 5, 2007
    Assignee: AstraZeneca AB
    Inventors: Moya Caffrey, Rhonan Ford, Austen Pimm
  • Adamantane derivatives
    Publication number: 20070082957
    Abstract: The invention provides adamantane derivatives of formula (I), a process for the their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Application
    Filed: September 29, 2006
    Publication date: April 12, 2007
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Chemical compounds
    Publication number: 20070032523
    Abstract: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: March 30, 2004
    Publication date: February 8, 2007
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
    Publication number: 20060160904
    Abstract: The invention provides compounds of formula (I) in which m, n, R?1, R?2, R?3, R?4 and R?5 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Application
    Filed: February 19, 2004
    Publication date: July 20, 2006
    Inventors: Moya Caffrey, Rhonan Ford, Austen Pimm
  • Adamantane derivatives
    Patent number: 6881754
    Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).
    Type: Grant
    Filed: December 12, 2000
    Date of Patent: April 19, 2005
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
  • Adamantane derivatives
    Publication number: 20030013704
    Abstract: 1
    Type: Application
    Filed: June 12, 2002
    Publication date: January 16, 2003
    Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis